Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...
ADC Therapeutics weighs ZYNLONTA safety risks in its LOTIS-5 trial against strategic cost alternatives. Read why ADCT stock ...
Shares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results